IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2023
- 12 September 2023 - 1 mins read
Aggregated presentation by day and by market
| Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 04/09/2023 | FR0010259150 | 40 | 116.99 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 04/09/2023 | FR0010259150 | 112 | 116.98 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 04/09/2023 | FR0010259150 | 20 | 116.20 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 04/09/2023 | FR0010259150 | 1,528 | 117.16 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/09/2023 | FR0010259150 | 19 | 115.40 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/09/2023 | FR0010259150 | 1,581 | 114.98 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/09/2023 | FR0010259150 | 227 | 115.14 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/09/2023 | FR0010259150 | 30 | 115.00 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/09/2023 | FR0010259150 | 1,343 | 114.87 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 07/09/2023 | FR0010259150 | 46 | 118.65 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 07/09/2023 | FR0010259150 | 1,554 | 117.04 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 08/09/2023 | FR0010259150 | 44 | 119.50 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 08/09/2023 | FR0010259150 | 1,556 | 119.62 | XPAR |
| * Two-digit rounding after the decimal | TOTAL | 8,100 | 116.75 | |||
Attachment
11 July 2024
6 mins read
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
09 July 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
09 July 2024
1 mins read
Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
08 July 2024
1 mins read
Half-year statement of IPSEN liquidity agreement – 2024 06 30
02 July 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
02 July 2024
9 mins read
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
25 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
18 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
11 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
10 June 2024
12 mins read